Biotech News

GENFIT Answers its Investors – Episode #3 - August 3, 2026

GENFIT (GNFT)GENFIT2026-08-03 14:32 ESTCompany update

Dear All, Following the previous episodes of our video series dedicated to the questions you have submitted, GENFIT is continuing this format of direct dialogue with its shareholders. In this third episode, Pascal Prigent, Chief Executive Officer of GENFIT, discusses the outlook for Iqirvo®

Related news

GNFTGENFIT2026-06-15 16:10 EST

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

GNFTGENFIT2026-02-12 17:35 EST

GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales

View all latest news

GENFIT

Liver-Disease Therapeutics and Diagnostics GENFIT develops therapies and diagnostic technologies for liver diseases. Its portfolio combines commercial economics from a partnered product with internal programs in cholangiocarcinoma and acute-on-chronic liver failure. Iqirvo Economics GENFIT receives milestones and royalties from Ipsen’s...

Recent company news

GNFTGENFIT2026-08-03 14:32 EST

GENFIT Answers its Investors – Episode #3 - August 3, 2026

GNFTGENFIT2026-07-08 16:00 EST

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GNFTGENFIT2026-07-02 16:05 EST

GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH

GNFTGENFIT2026-06-23 16:00 EST

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

GNFTGENFIT2026-06-15 16:10 EST

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States